In stock for ordering This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder. Publication ID SMA16-4938 Publication Date March 2016 Format Advisory More like this SAMHSA Advisory Download Advisory: Sublingual & Transmucosal Buprenorphine PDF 419.86 KB Order Print Publication Quantity Max Order Limit 25 Orders exceeding the maximum quantity limit require authorization. Find Related Information Audience Policymakers Professional Care Providers Program Planners, Administrators, & Project Managers Public Health Professionals Population Group People with Substance Use or Abuse Problems as Population Group Series SAMHSA Advisory You May Also Be Interested In Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs This guide informs clinicians about medications for opioid use disorder treatment, including side effects, drug interactions, and take-home doses. It discusses patient counseling, associated medical issues, hepatitis C evaluation, drug testing, and pregnant women. Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants This Clinical Guide provides comprehensive, national guidance for optimal management of pregnant and parenting women with opioid use disorder and their infants. The Clinical Guide helps healthcare professionals and patients determine the most clinically appropriate action for a particular situation and informs individualized treatment decisions. Pharmacologic Guidelines for Treating Individuals with Post-Traumatic Stress Disorder and Co-Occurring Opioid Use Disorders This manual offers guidelines for medication-assisted treatment for people, particularly veterans, living with post-traumatic stress disorder and co-occurring opioid use disorders. It covers screening, concomitant treatment, pharmacotherapy, and multiple misused substances. The Facts about Buprenorphine for Treatment of Opioid Addiction This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process. TIP 63: Medications for Opioid Use Disorder - Executive Summary The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery. Behavioral Health Equity Barometer, 2014 This report provides a snapshot of key aspects of behavioral health, serious mental illness, suicidal thoughts, and mental illness, substance use disorders, or both. The information is based on selected determinants of health, including race and ethnicity, income level, geography, and health insurance status.